Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2025
Treatment of Melasma Using Low-Fluence QS Nd: YAG (1064 nm) Laser: A Blind, Randomized, Placebo-Controlled Trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sadeghpour Mona, Laughter Melissa, Rizzo Sarah Ionto, Depina Joaninha, Petrell Kathy, Arndt Kenneth A, Dover Jeffrey S
Аннотация
BACKGROUND: Despite evidence supporting efficacy of low-fluence Q-switched (QS) neodymium-doped yttrium aluminum garnet (Nd:YAG) 1,064-nm lasers, treatment protocols are not standardized and limited to mostly retrospective, observational, or inadequately controlled studies.
OBJECTIVE: To investigate the safety and efficacy of low-fluence QS Nd:YAG (1,064 nm) laser in the treatment of melasma.
MATERIALS AND METHODS: A prospective, blind, randomized, placebo-controlled split face trial was conducted. Patients with Fitzpatrick skin types I-IV, and melasma severity scores of at least 2 received 3 monthly treatments using mechanical exfoliation, low-fluence QS Nd:YAG laser, hydroquinone 4% twice daily, and sunscreen.
RESULTS: Both treatment and control sides of the face showed a comparable decrease in melanin index (MI), with a statistically significant difference only after treatment 2 ( p = .04). The Modified Melasma and Severity Index (mMASI) score for both the treatment and control decreased but without any significant difference (.18 < p < .57). The highest level of patient-reported improvement occurred at week 8; however, patient-reported improvement decreased by the 6-month follow-up.
CONCLUSION: Placebo and laser treatment groups showed an effective, safe, yet similar decrease in both MI and mMASI scores, indicating that low-fluence, QS Nd:YAG laser treatments did not add significant benefit beyond combination topical therapies.
OBJECTIVE: To investigate the safety and efficacy of low-fluence QS Nd:YAG (1,064 nm) laser in the treatment of melasma.
MATERIALS AND METHODS: A prospective, blind, randomized, placebo-controlled split face trial was conducted. Patients with Fitzpatrick skin types I-IV, and melasma severity scores of at least 2 received 3 monthly treatments using mechanical exfoliation, low-fluence QS Nd:YAG laser, hydroquinone 4% twice daily, and sunscreen.
RESULTS: Both treatment and control sides of the face showed a comparable decrease in melanin index (MI), with a statistically significant difference only after treatment 2 ( p = .04). The Modified Melasma and Severity Index (mMASI) score for both the treatment and control decreased but without any significant difference (.18 < p < .57). The highest level of patient-reported improvement occurred at week 8; however, patient-reported improvement decreased by the 6-month follow-up.
CONCLUSION: Placebo and laser treatment groups showed an effective, safe, yet similar decrease in both MI and mMASI scores, indicating that low-fluence, QS Nd:YAG laser treatments did not add significant benefit beyond combination topical therapies.